Return to Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in pts with type 2 DM: the PERISCOPE trial.

Background

BioCritique references

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. SE Nissen et al. JAMA 2008 4;299(13):1561-73

Consensus statement on the worldwide standardization of the hemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. et al. Diabetes Care 2007 9;30(9):2399-400

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. BV Howard et al. JAMA 2008 4;299(14):1678-89

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. SE Nissen et al. JAMA 2008 4;299(13):1547-60

Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. RB Goldberg et al. Mayo Clin Proc 2006 12;81(12):1579-88

Progression of calcified coronary atherosclerosis: relationship to coronary risk factors and carotid intima-media thickness. AJ Taylor et al. Atherosclerosis 2008 3;197(1):339-45

Reduction in Blood Pressure With Statins: Results From the UCSD Statin Study, a Randomized Trial. BA Golomb et al. Arch Intern Med 2008 4;168(7):721-7

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. PM Ridker et al. Circulation 2003 11;108(19):2292-7

PubMed abstracts

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications. B Molavi et al. Vasc Health Risk Manag 2007 1;3(6):967-73

Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. CC Fang et al. Angiology 2007 10;58(5):523-34

Clinical thiazolidinediones as PPARgamma ligands with the potential for the prevention of cardiovascular disease in diabetes. ST de Dios et al. Curr Diabetes Rev 2006 5;2(2):227-39

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. SE Nissen et al. JAMA 2008 4;299(13):1561-73

Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes-Update 2008. A Rohatgi et al. Cardiovasc Drugs Ther 2008 3;():

Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome. AJ Drexler et al. Metab Syndr Relat Disord 2005 1;3(2):147-73

Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. J Yu et al. Metabolism 2007 10;56(10):1396-401

Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled study. RP Naoumova et al. J Am Coll Cardiol 2007 11;50(21):2051-8

Pioglitazone reduces atherogenic outcomes in type 2 diabetic patients. M Igarashi et al. J Atheroscler Thromb 2008 2;15(1):34-40

Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes. MG Bourassa et al. Curr Atheroscler Rep 2008 4;10(2):106-16

Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. T Mazzone et al. Am J Med 2007 9;120(9 Suppl 2):S26-32

Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus. VA Fonseca et al. Am J Med 2007 9;120(9 Suppl 2):S18-25

Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. DJ Hausenloy et al. Heart 2008 6;94(6):706-14

Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. A Ceriello et al. Diabetes Metab Res Rev 2008 1;24(1):14-26